The CFO, Secretary & Treasurer of KemPharm (KMPH) is Buying Shares


Today, the CFO, Secretary & Treasurer of KemPharm (NASDAQ: KMPH), Laduane Clifton, bought shares of KMPH for $1,651.

Following this transaction Laduane Clifton’s holding in the company was increased by 30.95% to a total of $7,123. In addition to Laduane Clifton, one other KMPH executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Currently, KemPharm has an average volume of 398.9K.

Starting in July 2018, KMPH received 7 Buy ratings in a row.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts